The COVID-19 pandemic caused by the SARS-CoV-2 virus, has changed the homeostasis of the medical world. In this critical phase, in addition to the general recommendations issued by World Health Organization (WHO) for medical practitioners and health care givers, certain other precautions and safe care practices need to be emphasized which are unique to each branch of medicine. Aesthetic dermatology is no exception. With aesthetic treatments on the rise, it is pertinent to formulate safe practices for aesthetic dermatology to protect the doctor, health staff and the patients from getting exposed during this phase and in the aftermath of the pandemic. Recommendations for surgical and dental procedures advice to defer such procedures. This can be extrapolated to aesthetic dermatology also, but once health care services start, there should be some safety recommendations to be followed until we have definitive management or a vaccine for it.

Persistence and hypertrophy of fat pads particularly of the face and neck region disturb beauty proportions, thus demand treatments. Phosphatidylcholine and deoxycholic acid are the most commonly used solutions for injection lipolysis. As we stand today, sodium deoxycholate preparation is approved by the US Food and Drug Administration for the same. This article describes the correct use of solution to achieve fat reduction and ensure safety. Complete details of patient selection, assessment, dosing, and injection techniques are described in this article. A brief note on posttreatment care and complications is also provided.

Introduction: Pruritus is a common and unpleasant symptom associated with multiple skin diseases. As histamine plays a central role in pruritus pathology, H1 antihistamines are frequently used in its management. Bilastine is a potent second-generation antihistamine approved for the management of urticaria. However, there are few studies showing its effectiveness and safety in pruritus associated with skin diseases. Materials and Methods: In this multicenter, open-label study, patients with pruritus associated with various skin diseases received bilastine 20 mg once daily for 4 weeks. Patients were evaluated for improvement in their pruritus based on the 5D itch score and Dermatology Life Quality Index (DLQI). Safety of bilastine was assessed by monitoring the incidence of adverse events during the study period. Results: A total of 116 patients with urticaria (n = 22), eczema/dermatitis (n = 27), lichen planus (n = 9), pPsoriasis (n = 11), dermatophytosis (n = 42), and others (n = 5) were included in the study. There was a significant improvement in the 5D itch score at the end of therapy (16.18 ± 2.81 vs. 6.20 ± 1.38 P < 0.0001) in all patients. Bilastine improved the DLQI at week 4 in all disease groups (11.83 ± 4.97 vs. 2.15 ± 2.68; P < 0.0001). The treatment was well tolerated. Conclusion: Bilastine is associated with significant improvement in pruritus associated with multiple dermatological disorders with a very good safety profile.

Background Scarring is a common and undesirable outcome of acne vulgaris. There are limited effective topical formulations for acne scar treatment. The investigational product, acne scar serum (HEXILAK® Acne Scar Serum) is latest topical formulation developed for treatment of acne scar with unique ingredients, Kollaren and Exo‐T. Objective Evaluate safety and efficacy of latest acne scar serum on the reduction of acne scars in Indian population. Materials and Methods Subjects, diagnosed clinically with acne scars with or without hyperpigmentation, of either gender in the age group of 15 to 45 years were enrolled in the study. The investigational acne scar serum was applied twice daily for 3 months with monthly follow for outcome evaluation. Results Out of 72 subjects enrolled, 67 completed the study. Most of the subjects, 79.1% showed improvement in acne scar at Day 90. Significant reduction of mean total post‐acne hyperpigmentation index (PAHI) was seen at all follow up visits compared with baseline. Significant improvement in mean acne scar depth, mean acne scar volume, and mean L value using 3D imaging were observed at all visits compared with baseline. All side effects reported were mild and overall, it was well tolerated by all subjects. Conclusion We found that there was a significant reduction in acne scar and post‐acne pigmentation with new acne scar serum as a monotherapy, this needs further confirmation in larger randomized controlled studies. Therefore, topical acne scar serum with unique ingredients Kollaren and Exo‐T can be a safe, effective, and new option in the armamentarium of acne scar management.

<p class="abstract"><strong>Background:</strong> Atopic dermatitis is considered as the most common chronic, inflammatory dermatological disorder. Skin barrier dysfunction represents an early pathology of this condition. Various factors contribute to development of such defects. Skin moisturizers remain the mainstay of therapy for AD along with other treatment modalities.</p><p class="abstract"><strong>Methods:</strong> Dermatologists across India were administered a questionnaire consisting of questions related to number of the patients seen with AD every week and their clinical experience regarding the use of novel skin moisturizer containing skin barrier therapy for the management of AD. The responses were analysed as number and percentages.<strong></strong></p><p class="abstract"><strong>Results:</strong> A total of 1605 patients were included in this survey. The complete responses were obtained from a total of 58 dermatologists. The majority (98%) of the dermatologists found the overall efficacy of novel skin moisturizer (Atoderm Intensive Baume) in AD patients as ‘satisfactory’. Atoderm Intensive Baume was found as efficacious in improving various parameters of AD such as skin dryness, severity of pruritus, inflammation, insomnia, itching, and urge to scratch. It was also well tolerated. It plays an important role in the repair of damaged skin barrier caused by AD.</p><p class="abstract"><strong>Conclusions:</strong> This survey findings indicated that novel skin moisturizer (Atoderm Intensive Baume) is a preferred formulation by dermatologists across India for the management of AD with proven efficacy and safety.</p>